Terms: = Kidney tumors AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Treatment
34 results:
1. NEIL3 promotes cell proliferation of ccRCC via the cyclin D1-Rb-E2F1 feedback loop regulation.
Zhang M; Jiang Y; Wang J; Yue Y; Liu W; Wang L; Li Y; Wang W; Cai H; Yang Z; Ma M; Lu S; Fan J
DNA Repair (Amst); 2024 Jan; 133():103604. PubMed ID: 37992567
[TBL] [Abstract] [Full Text] [Related]
2. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
3. Diosmetin suppresses the progression of ESCC by CDK2/Rb/E2F2/RRM2 pathway and synergies with cisplatin.
Chen Y; Dai X; Chen W; Qiao Y; Bai R; Duan X; Zhang K; Chen X; Li X; Mo S; Cao W; Li X; Liu K; Dong Z; Lu J
Oncogene; 2023 Jul; 42(29):2278-2293. PubMed ID: 37349644
[TBL] [Abstract] [Full Text] [Related]
4. SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors.
Huang Z; Li X; Tang B; Li H; Zhang J; Sun R; Ma J; Pan Y; Yan B; Zhou Y; Ding D; Yan Y; Jimenez R; Orme JJ; Jin X; Yang J; Huang H; Jia Z
Cancer Res; 2023 Mar; 83(6):875-889. PubMed ID: 36637424
[TBL] [Abstract] [Full Text] [Related]
5. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
[TBL] [Abstract] [Full Text] [Related]
6. Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with
Nelson LJ; Castro KE; Xu B; Li J; Dinh NB; Thompson JM; Woytash J; Kipp KR; Razorenova OV
Cell Cycle; 2022 May; 21(10):1103-1119. PubMed ID: 35240916
[TBL] [Abstract] [Full Text] [Related]
7. Brusatol inhibits the growth of renal cell carcinoma by regulating the PTEN/PI3K/AKT pathway.
Wang T; Chen Z; Chen H; Yu X; Wang L; Liu X
J Ethnopharmacol; 2022 Apr; 288():115020. PubMed ID: 35066068
[TBL] [Abstract] [Full Text] [Related]
8. Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Schultz CR; Swanson MA; Dowling TC; Bachmann AS
Cancer Chemother Pharmacol; 2021 Oct; 88(4):607-617. PubMed ID: 34129075
[TBL] [Abstract] [Full Text] [Related]
9. Purification of a novel protein with cytotoxicity against non-small-cell lung cancer cells from Boletus bicolor.
Zhang MH; Zhou R; Liu F; Ng TB
Arch Pharm (Weinheim); 2021 Sep; 354(9):e2100135. PubMed ID: 34076300
[TBL] [Abstract] [Full Text] [Related]
10. Dose escalation study of targeted alpha therapy with [
Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Pawlak D; Kuliński R; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3595-3605. PubMed ID: 33860346
[TBL] [Abstract] [Full Text] [Related]
11. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
12. Positively Charged Nanoparticle Delivery of n-Butylidenephthalide Enhances Antitumor Effect in Hepatocellular Carcinoma.
Chang KF; Huang XF; Lin YL; Liao KW; Hsieh MC; Chang JT; Tsai NM
Biomed Res Int; 2021; 2021():8817875. PubMed ID: 33791383
[TBL] [Abstract] [Full Text] [Related]
13. Prevalence, clinical features and prognosis of malignant solid tumors in infants: a 14-year study.
Zhi T; Zhang WL; Zhang Y; Wang YZ; Huang DS
Bosn J Basic Med Sci; 2021 Oct; 21(5):598-606. PubMed ID: 33259778
[TBL] [Abstract] [Full Text] [Related]
14. A fast full-wave solver for calculating ultrasound propagation in the body.
Haqshenas SR; Gélat P; van 't Wout E; Betcke T; Saffari N
Ultrasonics; 2021 Feb; 110():106240. PubMed ID: 32950757
[TBL] [Abstract] [Full Text] [Related]
15. Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer.
Chai D; Qiu D; Zhang Z; Yuchen Shi S; Wang G; Fang L; Li H; Li H; Tian H; Zheng J
J Cell Mol Med; 2020 Sep; 24(18):10744-10755. PubMed ID: 32725966
[TBL] [Abstract] [Full Text] [Related]
16. Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.
Chen D; Sun X; Zhang X; Cao J
Biomed Res Int; 2020; 2020():9525207. PubMed ID: 32626773
[TBL] [Abstract] [Full Text] [Related]
17. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y
Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
[TBL] [Abstract] [Full Text] [Related]
18. Effect of ghost pepper on cell proliferation, apoptosis, senescence and global proteomic profile in human renal adenocarcinoma cells.
Perla V; Nadimi M; Reddy R; Hankins GR; Nimmakayala P; Harris RT; Valluri J; Sirbu C; Reddy UK
PLoS One; 2018; 13(10):e0206183. PubMed ID: 30379886
[TBL] [Abstract] [Full Text] [Related]
19. H1/pAIM2 nanoparticles exert anti-tumour effects that is associated with the inflammasome activation in renal carcinoma.
Chai D; Liu N; Li H; Wang G; Song J; Fang L; Lu Z; Yao H; Zheng J
J Cell Mol Med; 2018 Nov; 22(11):5670-5681. PubMed ID: 30160343
[TBL] [Abstract] [Full Text] [Related]
20. AIM2 is a potential therapeutic target in human renal carcinoma and suppresses its invasion and metastasis via enhancing autophagy induction.
Chai D; Shan H; Wang G; Li H; Fang L; Song J; Zhang Q; Bai J; Zheng J
Exp Cell Res; 2018 Sep; 370(2):561-570. PubMed ID: 30031129
[TBL] [Abstract] [Full Text] [Related]
[Next]
